Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Arvinas (Nasdaq: ARVN), a clinical-stage biotechnology company focused on developing targeted protein degradation drugs, has announced its upcoming third quarter 2024 financial results and corporate update webcast. The event is scheduled for Wednesday, October 30, 2024, at 8:00 a.m. ET.

Investors and interested parties can access the live webcast through the 'Events and Presentations' section on the company's investor page. For those unable to attend the live event, a replay will be made available on the Arvinas website following the presentation.

News Market Reaction 1 Alert

-4.98% News Effect

On the day this news was published, ARVN declined 4.98%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

10/21/2024 - 07:00 AM

NEW HAVEN, Conn., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review third quarter 2024 financial results and provide a corporate update during a live webcast on Wednesday, October 30, 2024, at 8:00 a.m. ET.

The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website following the completion of the event.

About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC^® (PROteolysis Targeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.

Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com

Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com